GlassScriptPhysician profile
Leondrea Collins
NPI 1639608813
$27,757.33
in general payments reported to CMS, 2019-2025
16 companies · $9,188 in 2025
The $9,188 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.10 · 2022: $357 · 2023: $2,384 · 2024: $16K · 2025: $9,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $4,575 · Food and Beverage: $4,418 · Consulting Fee: $4,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,040.00 |
| Travel and Lodging | $4,575.49 |
| Food and Beverage | $4,418.09 |
| Consulting Fee | $4,350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $23,988.17 | 2022-2025 | Spravato, Invega Sustenna |
| Neuronetics, INC. | $1,491.78 | 2023 | Neurostar Tms Therapy System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $533.69 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $355.19 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $253.23 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $231.99 | 2022-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $224.67 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $191.92 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Vanda Pharmaceuticals INC. | $150.81 | 2022-2025 | Fanapt, Hetlioz |
| Indivior INC. | $116.15 | 2022-2023 | Perseris |
| Tris Pharma INC | $107.23 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.86 | 2025 | Cobenfy |
| Alkermes, INC. | $28.03 | 2023 | Aristada, Lybalvi |
| Arbor Pharmaceuticals, INC. | $17.10 | 2021 | |
| Novo Nordisk INC | $15.22 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leondrea Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.